Abstracts tagged "Autoantibody(ies)"

Abstract Number: 1792 • ACR Convergence 2024
CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus
Lauren Robinson¹, Preetha Balasubramanian², Zurong Wan², Juan Rodriguez Alcazar², Marina Lima Silva Santos², Lynnette Walters³, Jeanine Baisch², Karen Onel⁴, Tracey Wright⁵, Virginia Pascual⁶ and Simone Caielli², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Scottish Rite Hospital for Children, Allen, TX, ⁴HSS, New York, NY, ⁵UT Southwestern, Plano, TX, ⁶Weill Cornell Medical College, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature.…
Abstract Number: 2294 • ACR Convergence 2024
Pharmacodynamic Effects of Nipocalimab on Disease Biomarkers in Patients with Moderate-to-Severe Active Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2 Study
Kathy Sivils¹, Steven Leonardo², He Li³, Keying Ma⁴, Matthew J. Loza⁵, Jonathan J. Hubbard⁴, Kim Campbell⁴ and Sheng Gao⁴, ¹Johnson & Johnson Innovative Medicine, Edmond, OK, ²Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA, ³Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁴Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁵Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, USA, Spring House, PA
Background/Purpose: Nipocalimab is a fully human, immunoglobulin G (IgG) 1 monoclonal antibody that selectively binds to the IgG-binding site of the neonatal crystallizable fragment receptor…
Abstract Number: 2669 • ACR Convergence 2024
Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies
Hannah Bulgart¹, Kassidy Banford², Shane Bruckner³, Kevin McElhanon², Nicholas Young¹, Brian Paleo², Eric Beck², Rohit Aggarwal⁴, Chester Oddis⁵, Braden Zeno⁶, Wael Jarjour⁷ and Noah Weisleder³, ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University, Columbus, ³Ohio State University, Columbus, OH, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Ohio State University, upper arlington, OH, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Idiopathic immune myopathies (IIMs) are a group of autoimmune diseases that produce chronic inflammation and degeneration of skeletal muscle structure and function. One process…
Abstract Number: 0186 • ACR Convergence 2024
Development of a Novel Dried Blood Spot Method to Improve Capacity for ANA Testing in Lower-Resource Settings
Ekemini Ogbu¹, Stela Florea², Donna Diorio², Somak Roy², Dhriti Sharma², Michael Henrickson², Patricia Vega-Fernandez², Angela Migowa³, Sarangarajan Ranganathan² and hermine brunner¹, ¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³AGA KHAN UNIVERSITY, Nairobi, Kenya
Background/Purpose: Timely diagnosis of children and young adults with rheumatologic disorders remains a global challenge especially in lower-resource settings. There is limited access to diagnostic…
Abstract Number: 0642 • ACR Convergence 2024
Anti-Myxovirus Resistance Protein 1: A Novel Biomarker for Autoimmune Myositis and Interstitial Lung Disease in Systemic Lupus Erythematosus
Eugene Krustev¹, Marvin Fritzler², Sasha Bernatsky³, Yvan St-Pierre⁴, Evelyne Vinet⁵, Christian Pineau⁶, Arielle Mendel⁷, Faras Kalache⁸, Louis-Pierre Grenier⁸, Thaisa Cotton⁸, Omid Zahedi⁹ and May Choi¹, ¹University of Calgary, Calgary, AB, Canada, ²Mitogen Diagnostics Corp, Calgary, AB, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷Division of Rheumatology, Department of Medicine, McGill University and Centre for Outcomes Research and Evaluation, McGill University Health Centre, Montreal, QC, Canada, ⁸Division of Rheumatology, Department of Medicine, McGill University, Montreal, QC, Canada, ⁹Division of Rheumatology, Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada
Background/Purpose: Although autoimmune myositis (AIM) and interstitial lung disease (ILD) are uncommon in systemic lupus erythematosus (SLE), they are associated with worse outcomes. Myxovirus Resistance…
Abstract Number: 1153 • ACR Convergence 2024
Increased Prevalence of Myositis Specific and Associated Autoantibodies in Patients with Interstitial Lung Disease of Unknown Etiology
Vasiliki Koulouri¹, Ilektra Voulgareli², Sofia Flouda³, Nikoletta Galanopoulou⁴, Nikolaos Marketos⁵, Charalampos Skarlis⁵, Sylvia Raftopoulou⁵, Kyriaki Tavernaraki⁶, Alexia Chronaiou², Georgios Tsoukalas², Nikolaos Zias⁷, Dimitrios Boumpas⁸ and Clio Mavragani⁹, ¹Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Greece, Athens, Greece, ²4th Respiratory Medicine Department, Sotiria General and Chest Diseases Hospital, Athens, Greece, Athens, Greece, ³4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, ⁴10th Respiratory Medicine Department, Sotiria General and Chest Diseases Hospital, Athens, Greece, ⁵Molecular and Applied Physiology Unit, Department of Physiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece, ⁶Imaging and Interventional Radiology, Sotiria General and Chest Diseases Hospital, Athens, Greece, Athens, Greece, ⁷Respiratory Medicine Department, Athens Naval Hospital, Athens, Greece, ⁸4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece, ⁹Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece
Background/Purpose: In recent years, connective tissue diseases (CTDs) have been increasingly recognized as a significant underlying pathology of interstitial lung diseases (ILDs). Amongst CTDs, idiopathic…
Abstract Number: 1575 • ACR Convergence 2024
Anti-U1RNP Antibodies Are Associated with a Distinct Clinical Phenotype and a Worse Survival in Patients with Systemic Sclerosis
Kevin Chevalier¹, Guillaume Chassagnon², Sarah LOUIS-LEONARD³, Pascal cohen⁴, bertrand Dunogue⁵, Alexis Régent⁶, Benjamin Thoreau⁵, Luc Mouthon⁵ and Benjamin Chaigne⁷, ¹Paris Cardiovascular Research Center, INSERM U970, Paris, France, ²Department of Radiology, Hôpital Cochin, AP-HP. Centre Université Paris Cité, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France, Paris, France, ³Sorbonne Université, INSERM, Department of Neurormyologie and Neuropathology, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁷Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Systemic sclerosis (SSc) is a rare systemic disease within the connective tissue disease (CTD) spectrum. It is characterized by microcirculatory abnormalities, skin and internal…
Abstract Number: 1801 • ACR Convergence 2024
Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus
Tania Rowley¹, Adnan R. Khan¹, Laura McLaughlin¹, Hannah Cherry¹, Farnaz Fallah-Arani¹, Yiannis Ioannou¹, Debasish Pyne² and Anthony Shock¹, ¹UCB Pharma, Slough, United Kingdom, ²Barts Health NHS Trust, London, United Kingdom
Background/Purpose: The pivotal role of CD40-CD40L interactions in systemic lupus erythematosus (SLE) pathogenesis stems from the orchestration of a range of immune and inflammatory responses…
Abstract Number: 2295 • ACR Convergence 2024
Association of Early Markers in Patients with Sjögren’s Syndrome in a Diverse Academic Cohort
Danielle Henry¹ and Schartess Culpepper Pace², ¹University of Miami at Holy Cross Health, Fort Lauderdale, FL, ²University of Miami, Pembroke Pines, FL
Background/Purpose: Sjogren’s syndrome (SS) is a heterogenous systemic inflammatory autoimmune disease characterized by sicca symptoms. It affects 0.3-1 per 1000 of the general population1. Studies…
Abstract Number: 0005 • ACR Convergence 2024
Autoantibodies Identified in Myositis-Specific Autoantibody Negative Juvenile Myositis Patients
FIONNUALA MCMORROW¹, Lisa Rider², Neil McHugh¹ and Sarah Tansley¹, ¹University of Bath, Bath, United Kingdom, ²NIEHS, NIH, Garrett Park, MD
Background/Purpose: Myositis autoantibodies are important clinical biomarkers however, around 40% of patients with juvenile myositis (JM) are classified as ‘autoantibody negative’ (1) and therefore cannot…
Abstract Number: 0285 • ACR Convergence 2024
Anti-THSD7A Antibodies Are Not Broadly Associated with IgG4-Related Disease or IgG4-Related Membranous Nephropathy
Guy Katz¹, Jesse Akaa², Grace McMahon¹, Isha Jha¹, Ian Doyle¹, Ana Fernandes¹, Zachary Wallace³, Shiv Pillai⁴, John Stone⁵ and Cory Perugino¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachussets General Hospital, Boston, MA, ³Massachusetts General Hospital, Newton, MA, ⁴Harvard Medical School, Cambridge, MA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Membranous nephropathy (MN) is a known manifestation of IgG4-related disease (IgG4-RD). Unlike primary MN, most patients with IgG4-related MN do not have anti-phospholipase 2…
Abstract Number: 0669 • ACR Convergence 2024
Efficacy of Belimumab in Systemic Lupus Erythematosus: A Single-Centre Retrospective Study
buddhika Jayaratna¹, Pasan Serasinghe², Louise Nel³, Sahil Jain³, Shrish Sangle², Begona Lopez¹, Giovanni Sanna², Michelle Fernando¹ and David DCruz⁴, ¹Guys & St Thomas NHS Foundation Trust, London, United Kingdom, ²Guys & St Thomas NHS Foundation Trust, London, England, United Kingdom, ³Guys and St Thomas' Hospital, London, United Kingdom, ⁴The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multi-system autoimmune rheumatic disorder. Despite therapeutic advances, managing SLE remains challenging due to its complex pathogenesis and…
Abstract Number: 1154 • ACR Convergence 2024
Comparative Transcriptome Analysis of Murine Model and Human Samples in Anti-Melanoma Differentiation Associated Gene 5 Antibody-positive Rapidly Progressive Interstitial Lung Disease
Yuki Ichimura¹, Risa Konishi², Tadatsune Iida³, Kousuke Negishi⁴ and Naoko Okiyama⁵, ¹Tokyo Women’s Medical University, Tokyo, Japan, ²University of Tsukuba, Tokyo, Japan, ³Institute of Science Tokyo, Tokyo, Japan, ⁴Kawakita General Hospital, Tokyo, Japan, ⁵Institute of Science Tokyo, Toky, Japan
Background/Purpose: Anti-Melanoma differentiation associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) frequently presents with rapidly progressive interstitial lung disease (RP-ILD), leading to a high mortality rate…
Abstract Number: 1580 • ACR Convergence 2024
Overt Polyautoimmunity and Its Risk Factors in a Multicenter Cohort of Systemic Sclerosis Patients
Irene Carrión-Barberà¹, Laura Tío², Laura Triginer², María Lee², Alfredo Guillén-del Castillo³, Anna Ribes², Lidia Valencia Muntalà⁴, Jordi Monfort¹, Tarek Carlos Salman Monte:⁵, Carmen PIlar Simeón-Aznar³, Anna Pros¹ and Javier Narvaez-García⁶, ¹Hospital del Mar, Barcelona, Spain, ²Hospital del Mar Research Institute, Barcelona, Spain, ³Hospital Vall d'Hebron, Barcelona, Spain, ⁴Hospital de Bellvitge, Barcelona, Spain, ⁵Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Overt PolyA (the clinical coexistence of ≥2 autoimmune diseases (AID) that fulfill classification criteria), is a frequent phenomenon in systemic sclerosis (SSc). However, the…
Abstract Number: 1833 • ACR Convergence 2024
Immune Complexes of Antibodies Directed to Angiotensin Receptor type-1 and Extracellular Vesicles Are Unique Modulators Contributing to Systemic Sclerosis
Alexander Maximilian Hackel¹, Marieke Leiber¹, Maike Winziers¹, Gabriela Riemekasten² and Reza Akbarzadeh¹, ¹Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany, ²University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany
Background/Purpose: Antibodies (Abs) directed against the angiotensin II type-1 receptor (AT1R) and extracellular vesicles (EVs) derived from systemic sclerosis (SSc) patients have the potential to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].